Key Insights

Highlights

Success Rate

93% trial completion (above average)

Research Maturity

67 completed trials (79% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.9%

5 terminated out of 85 trials

Success Rate

93.1%

+6.5% vs benchmark

Late-Stage Pipeline

6%

5 trials in Phase 3/4

Results Transparency

12%

8 of 67 completed with results

Key Signals

8 with results93% success

Data Visualizations

Phase Distribution

74Total
Not Applicable (8)
P 1 (40)
P 2 (21)
P 3 (5)

Trial Status

Completed67
Unknown6
Terminated5
Withdrawn4
Recruiting3

Trial Success Rate

93.1%

Benchmark: 86.5%

Based on 67 completed trials

Clinical Trials (85)

Showing 20 of 20 trials
NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT04907643Not ApplicableRecruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

NCT06715839Not ApplicableRecruiting

Target-specific immunoPET Imaging of Digestive System Carcinoma

NCT03771508Completed

Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments (SODA)

NCT06582849Not ApplicableCompleted

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

NCT03345563Not ApplicableCompleted

Project HERO: Health Empowerment & Recovery Outcomes

NCT05450393Withdrawn

Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study)

NCT05471401Not ApplicableWithdrawn

GI Organ Tracking Via Balloon Applicators

NCT00445965Phase 2Completed

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT04476082Completed

Nutrition in Gastrointestinal Tumors

NCT02489422Not ApplicableCompleted

Programs To Support You During Chemotherapy

NCT00416351Phase 1Completed

Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00003687Phase 3Completed

Treatment for Chronic Pain in Patients With Advanced Cancer

NCT00036790Phase 1Completed

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

NCT00049712Phase 1Completed

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

NCT03958188Unknown

PreOPerative Imaging of NeuroEndocrine Tumors

NCT00005639Phase 1Completed

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

NCT00621036Phase 2Withdrawn

Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma

NCT00019474Phase 2Completed

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

NCT00569309Not ApplicableCompleted

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Scroll to load more

Research Network

Activity Timeline